Lipoprotein (a), or Lp(a), is a type of LDL cholesterol. Your Lp(a) level is determined by your genes and isn't generally affected by lifestyle.
High levels of Lp(a) may be a sign of increased risk of heart disease, though it's not clear how much risk. Your doctor might order an Lp(a) test if you already have atherosclerosis or heart disease but appear to have otherwise normal cholesterol levels.
Lp(a) is often tested if you have a family history of early-onset heart disease or sudden death.
Drugs are in development to lower Lp(a), but it isn't yet clear what effect lowering Lp(a) will have on heart disease risk. People with high Lp(a) are generally advised to keep a low LDL cholesterol level.
This new test measures levels of ceramides in the blood. Ceramides are produced by all cells and play a significant role in the growth, function and ultimately death of many types of tissue. Ceramides are transported through the blood by lipoproteins and are associated with atherosclerosis.
Three specific ceramides have been linked to plaque buildup in the arteries and insulin resistance. Elevated levels of these ceramides in the blood indicates a higher risk of cardiovascular disease within one to five years.
Brain natriuretic peptide, also called B-type natriuretic peptide (BNP), is a protein that your heart and blood vessels produce. BNP helps your body eliminate fluids, relaxes blood vessels and funnels sodium into your urine.
When your heart is damaged, your body secretes high levels of BNP into your bloodstream to try to ease the strain on your heart. BNP levels may also rise if you have new or increasing chest pain (unstable angina) or after a heart attack.
Your BNP level can help in the diagnosis and evaluation of heart failure and other heart conditions. Normal levels vary according to age and gender and whether you are overweight. One of the most important uses of BNP is to try to sort out whether shortness of breath is due to heart failure.
For people who have heart failure, establishing a baseline BNP can be helpful and future tests can be used to help gauge how well your treatment works. A variation of BNP called N-terminal BNP also is useful in diagnosing heart failure and in some laboratories is used instead of BNP. N-terminal BNP may also be useful in evaluating your risk of a heart attack and other problems if you already have heart disease.
A high level of BNP alone isn't enough to diagnose a heart problem. Your doctor will also consider your risk factors and other blood test results.
Dec. 07, 2016
See more In-depth
- Wilson PWF. Heart disease. Lab Tests Online. https://labtestsonline.org/understanding/conditions/heart/start/3. Accessed Oct. 16, 2016.
- Wilson PWF, et al. Overview of the possible risk factors for cardiovascular disease. http://www.uptodate.com/home. Accessed Oct. 17, 2016.
- Heart-health screenings. American Heart Association. http://www.heart.org/HEARTORG/Conditions/Heart-Health-Screenings_UCM_428687_Article.jsp#.WAV8aMkmGLU. Accessed Oct. 17, 2016.
- LeBlond RF, et al., eds. Common laboratory tests. In: DeGowin's Diagnostic Examination. 10th ed. New York, N.Y.: McGraw-Hill Education; 2015. http://www.accessmedicine.com. Accessed Oct. 18, 2016.
- Lipoprotein metabolism profile. Mayo Medical Laboratories. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/83673. Accessed Oct. 19, 2016.
- Cholesterol and heart disease. American Heart Association's Go Red for Women. https://www.goredforwomen.org/know-your-risk/factors-that-increase-your-risk-for-heart-disease/cholesterol-heart-disease/. Accessed Oct. 19, 2016.
- Rosenson RS, et al. Measurement of blood lipids and lipoproteins. http://www.uptodate.com/home. Accessed Nov. 9, 2016.
- Morrow DA, et al. C-reactive protein in cardiovascular disease. http://www.uptodate.com/home. Accessed Oct. 17, 2016.
- C-reactive protein, high sensitivity, serum. Mayo Medical Laboratories. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/82047. Accessed Oct. 18, 2016.
- Morrow DA. Screening for cardiovascular risk with c-reactive protein. http://www.uptodate.com/home. Accessed Oct. 17, 2016.
- Nordestgaard BG, et al. Lipoprotein(a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. Journal of Lipid Research. In press. Accessed Oct. 16, 2016.
- Wallace ML, et al. Screening strategies for cardiovascular disease in asymptomatic adults. Primary Care: Clinics in Office Practice. 2014;41:371.
- Lim GB. Early-phase trials of lipoprotein(a) lowering. Nature Reviews Cardiology. In press. Accessed Oct. 16, 2016.
- Chaurasia B, et al. Ceramides – Lipotoxic inducers of metabolic disorders. Trends in Endocrinology & Metabolism. 2015;26:538.
- Klevstig M, et al. Targeting acid sphingomyelinase reduces cardiac ceramide accumulation in the post-ischemic heart. Journal of Molecular and Cellular Cardiology. 2016;93:69.
- Ceramides, plasma. Mayo Medical Laboratories. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/65054. Accessed Nov. 9, 2016.
- Chen HH, et al. Natriuretic peptide measurement in non-heart failure settings. http://www.uptodate.com/home. Accessed Oct. 17, 2016.
- Colucci WS, et al. Natriuretic peptide measurement in heart failure. http://www.uptodate.com/home. Accessed Oct. 17, 2016.